FibroGen INC is expected to hold their IPO on November 14, 2014. They are attempting to raise around 125 – 155 million dollars with the IPO. IPOs can be risky business, much more riskier than our S&P 500 stocks, however, if you want in on the Fibrogen Inc IPO…read on…
About Fibrogen INC
Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Fibrogen’s main focus is on treating anemia in patients with chronic kidney disease.
FibroGen’s primary candidate is called Roxadustat. It is an oral small molecule inhibitor of HIF prolyl hydroxylases.
FibroGen is currently in Phase 3 trials for the treatment of anemia in chronic kidney disease, or CKD.
FibroGen claims that its drub is safer, works better and is m ore convenient than the current methods of care for anemia in kidney patients. The current standard of care is based on injections. If you can replace an injection with an oral alternative, your odds of acceptance are usually much higher.
Fibrogen also has a second candidate which is in Phase 2 trials and will treat idipoathic pulmonary fibrosis, pancreatic cancer and liver fibrosis.
It is noteworthy to state that Goldman Sachs is the lead underwriter of the 2014 FibroGen IPO.
The San Francisco, CA-based company, which was founded in 1993, plans to list on the NASDAQ, though it has not selected a ticker.
Should I Invest In The FibroGen IPO 2014?
As with all IPOs and especially those in the biotech industry, it is risky – especially since the fate of the stock lies in successful Phase 3 clinical trials being successful. This is one of those plays that may be a good bet if you have some cash you’re willing to risk.